Which has higher earnings & valuation, IMUX or MIRA?

Immunic is trading at a lower price-to-earnings ratio than MIRA Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Immunic N/A N/A -$97.17M -$4.38 N/A MIRA Pharmaceuticals N/A N/A -$10.44M -$1.24 N/A

Is IMUX or MIRA more profitable?

MIRA Pharmaceuticals' return on equity of -106.95% beat Immunic's return on equity. Company Net Margins Return on Equity Return on Assets Immunic N/A -157.89% -107.88% MIRA Pharmaceuticals N/A -106.95% -104.18%

Which has better valuation and earnings, NMRA or MIRA?

MIRA Pharmaceuticals is trading at a lower price-to-earnings ratio than Neumora Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Neumora Therapeutics N/A N/A -$236.93M -$1.23 N/A MIRA Pharmaceuticals N/A N/A -$10.44M -$1.24 N/A

Is NMRA or MIRA more profitable?

MIRA Pharmaceuticals' return on equity of -106.95% beat Neumora Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Neumora Therapeutics N/A -242.28% -131.32% MIRA Pharmaceuticals N/A -106.95% -104.18%

Does the media favor NMRA or MIRA?

In the previous week, MIRA Pharmaceuticals had 3 more articles in the media than Neumora Therapeutics. MarketBeat recorded 5 mentions for MIRA Pharmaceuticals and 2 mentions for Neumora Therapeutics. Neumora Therapeutics' average media sentiment score of 0.67 beat MIRA Pharmaceuticals' score of 0.17 indicating that Neumora Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Neumora Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive MIRA Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer MIRA or MNOV?

In the previous week, MediciNova had 1 more articles in the media than MIRA Pharmaceuticals. MarketBeat recorded 6 mentions for MediciNova and 5 mentions for MIRA Pharmaceuticals. MediciNova's average media sentiment score of 0.23 beat MIRA Pharmaceuticals' score of 0.17 indicating that MediciNova is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MIRA Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral MediciNova 0 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is UNCY or MIRA more profitable?

Unicycive Therapeutics' return on equity of -91.50% beat MIRA Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Unicycive Therapeutics N/A -91.50% -61.47% MIRA Pharmaceuticals N/A -106.95% -104.18%

Does the media favor UNCY or MIRA?

In the previous week, Unicycive Therapeutics had 8 more articles in the media than MIRA Pharmaceuticals. MarketBeat recorded 13 mentions for Unicycive Therapeutics and 5 mentions for MIRA Pharmaceuticals. MIRA Pharmaceuticals' average media sentiment score of 0.17 beat Unicycive Therapeutics' score of 0.04 indicating that MIRA Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Unicycive Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 12 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral MIRA Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

MIRA Pharmaceuticals (MIRA) Competitors

$0.86 -0.05 (-5.33%)

Closing price 09/23/2026 04:00 PM Eastern

Extended Trading

$0.90 +0.04 (+4.70%)

As of 04:08 AM Eastern

Compare

MIRA vs. IMUX, NMRA, MNOV, NRXP, and UNCY

Should you buy MIRA Pharmaceuticals stock or one of its competitors? MIRA Pharmaceuticals's main competitors and comparable companies include Immunic (IMUX), Neumora Therapeutics (NMRA), MediciNova (MNOV), NRx Pharmaceuticals (NRXP), and Unicycive Therapeutics (UNCY). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does MIRA Pharmaceuticals compare to Immunic?

Immunic (NASDAQ:IMUX) and MIRA Pharmaceuticals (NASDAQ:MIRA) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, institutional ownership, dividends, earnings, analyst recommendations, media sentiment and profitability.

Immunic is trading at a lower price-to-earnings ratio than MIRA Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunic	N/A	N/A	-$97.17M	-$4.38	N/A
MIRA Pharmaceuticals	N/A	N/A	-$10.44M	-$1.24	N/A

Immunic has a beta of 1.41, suggesting that its share price is 41% more volatile than the broader market. Comparatively, MIRA Pharmaceuticals has a beta of 1.52, suggesting that its share price is 52% more volatile than the broader market.

MIRA Pharmaceuticals' return on equity of -106.95% beat Immunic's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immunic	N/A	-157.89%	-107.88%
MIRA Pharmaceuticals	N/A	-106.95%	-104.18%

Immunic currently has a consensus target price of $47.25, suggesting a potential upside of 404.27%. MIRA Pharmaceuticals has a consensus target price of $3.50, suggesting a potential upside of 308.07%. Given Immunic's stronger consensus rating and higher probable upside, equities analysts plainly believe Immunic is more favorable than MIRA Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunic	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	3 Strong Buy rating(s)	3.00
MIRA Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

In the previous week, MIRA Pharmaceuticals had 5 more articles in the media than Immunic. MarketBeat recorded 5 mentions for MIRA Pharmaceuticals and 0 mentions for Immunic. MIRA Pharmaceuticals' average media sentiment score of 0.17 beat Immunic's score of 0.00 indicating that MIRA Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Immunic	Neutral
MIRA Pharmaceuticals	Neutral

51.8% of Immunic shares are held by institutional investors. Comparatively, 35.2% of MIRA Pharmaceuticals shares are held by institutional investors. 5.5% of Immunic shares are held by company insiders. Comparatively, 19.9% of MIRA Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

MIRA Pharmaceuticals beats Immunic on 9 of the 14 factors compared between the two stocks.

How does MIRA Pharmaceuticals compare to Neumora Therapeutics?

Neumora Therapeutics (NASDAQ:NMRA) and MIRA Pharmaceuticals (NASDAQ:MIRA) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, earnings, institutional ownership, profitability, dividends, media sentiment, valuation and risk.

47.7% of Neumora Therapeutics shares are held by institutional investors. Comparatively, 35.2% of MIRA Pharmaceuticals shares are held by institutional investors. 26.9% of Neumora Therapeutics shares are held by company insiders. Comparatively, 19.9% of MIRA Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

MIRA Pharmaceuticals is trading at a lower price-to-earnings ratio than Neumora Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neumora Therapeutics	N/A	N/A	-$236.93M	-$1.23	N/A
MIRA Pharmaceuticals	N/A	N/A	-$10.44M	-$1.24	N/A

Neumora Therapeutics has a beta of 2.71, indicating that its stock price is 171% more volatile than the broader market. Comparatively, MIRA Pharmaceuticals has a beta of 1.52, indicating that its stock price is 52% more volatile than the broader market.

MIRA Pharmaceuticals' return on equity of -106.95% beat Neumora Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neumora Therapeutics	N/A	-242.28%	-131.32%
MIRA Pharmaceuticals	N/A	-106.95%	-104.18%

Neumora Therapeutics presently has a consensus target price of $6.57, indicating a potential upside of 798.60%. MIRA Pharmaceuticals has a consensus target price of $3.50, indicating a potential upside of 308.07%. Given Neumora Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Neumora Therapeutics is more favorable than MIRA Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neumora Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78
MIRA Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

In the previous week, MIRA Pharmaceuticals had 3 more articles in the media than Neumora Therapeutics. MarketBeat recorded 5 mentions for MIRA Pharmaceuticals and 2 mentions for Neumora Therapeutics. Neumora Therapeutics' average media sentiment score of 0.67 beat MIRA Pharmaceuticals' score of 0.17 indicating that Neumora Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Neumora Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
MIRA Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Neumora Therapeutics beats MIRA Pharmaceuticals on 10 of the 14 factors compared between the two stocks.

How does MIRA Pharmaceuticals compare to MediciNova?

MIRA Pharmaceuticals (NASDAQ:MIRA) and MediciNova (NASDAQ:MNOV) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, dividends, earnings, valuation, media sentiment, profitability and analyst recommendations.

MIRA Pharmaceuticals has a net margin of 0.00% compared to MediciNova's net margin of -1,168.70%. MediciNova's return on equity of -26.51% beat MIRA Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MIRA Pharmaceuticals	N/A	-106.95%	-104.18%
MediciNova	-1,168.70%	-26.51%	-24.39%

35.2% of MIRA Pharmaceuticals shares are held by institutional investors. Comparatively, 9.9% of MediciNova shares are held by institutional investors. 19.9% of MIRA Pharmaceuticals shares are held by insiders. Comparatively, 14.0% of MediciNova shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

MIRA Pharmaceuticals has a beta of 1.52, indicating that its share price is 52% more volatile than the broader market. Comparatively, MediciNova has a beta of 0.63, indicating that its share price is 37% less volatile than the broader market.

MIRA Pharmaceuticals has higher earnings, but lower revenue than MediciNova. MediciNova is trading at a lower price-to-earnings ratio than MIRA Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MIRA Pharmaceuticals	N/A	N/A	-$10.44M	-$1.24	N/A
MediciNova	$410K	336.14	-$12M	-$0.21	N/A

In the previous week, MediciNova had 1 more articles in the media than MIRA Pharmaceuticals. MarketBeat recorded 6 mentions for MediciNova and 5 mentions for MIRA Pharmaceuticals. MediciNova's average media sentiment score of 0.23 beat MIRA Pharmaceuticals' score of 0.17 indicating that MediciNova is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MIRA Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
MediciNova	0 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

MIRA Pharmaceuticals presently has a consensus price target of $3.50, suggesting a potential upside of 308.07%. MediciNova has a consensus price target of $7.75, suggesting a potential upside of 176.79%. Given MIRA Pharmaceuticals' higher probable upside, research analysts clearly believe MIRA Pharmaceuticals is more favorable than MediciNova.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MIRA Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
MediciNova	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71

Summary

MediciNova beats MIRA Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

How does MIRA Pharmaceuticals compare to NRx Pharmaceuticals?

MIRA Pharmaceuticals (NASDAQ:MIRA) and NRx Pharmaceuticals (NASDAQ:NRXP) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, profitability, earnings, dividends, institutional ownership, media sentiment, analyst recommendations and risk.

In the previous week, MIRA Pharmaceuticals had 5 more articles in the media than NRx Pharmaceuticals. MarketBeat recorded 5 mentions for MIRA Pharmaceuticals and 0 mentions for NRx Pharmaceuticals. MIRA Pharmaceuticals' average media sentiment score of 0.17 beat NRx Pharmaceuticals' score of 0.00 indicating that MIRA Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
MIRA Pharmaceuticals	Neutral
NRx Pharmaceuticals	Neutral

MIRA Pharmaceuticals has a beta of 1.52, meaning that its share price is 52% more volatile than the broader market. Comparatively, NRx Pharmaceuticals has a beta of 2.19, meaning that its share price is 119% more volatile than the broader market.

MIRA Pharmaceuticals has higher earnings, but lower revenue than NRx Pharmaceuticals. NRx Pharmaceuticals is trading at a lower price-to-earnings ratio than MIRA Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MIRA Pharmaceuticals	N/A	N/A	-$10.44M	-$1.24	N/A
NRx Pharmaceuticals	$1.23M	111.24	-$28.62M	-$0.55	N/A

MIRA Pharmaceuticals presently has a consensus price target of $3.50, suggesting a potential upside of 308.07%. NRx Pharmaceuticals has a consensus price target of $34.50, suggesting a potential upside of 991.77%. Given NRx Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe NRx Pharmaceuticals is more favorable than MIRA Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MIRA Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
NRx Pharmaceuticals	2 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.43

MIRA Pharmaceuticals has a net margin of 0.00% compared to NRx Pharmaceuticals' net margin of -691.81%. NRx Pharmaceuticals' return on equity of 0.00% beat MIRA Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MIRA Pharmaceuticals	N/A	-106.95%	-104.18%
NRx Pharmaceuticals	-691.81%	N/A	-63.92%

35.2% of MIRA Pharmaceuticals shares are owned by institutional investors. Comparatively, 4.3% of NRx Pharmaceuticals shares are owned by institutional investors. 19.9% of MIRA Pharmaceuticals shares are owned by insiders. Comparatively, 6.4% of NRx Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

NRx Pharmaceuticals beats MIRA Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

How does MIRA Pharmaceuticals compare to Unicycive Therapeutics?

Unicycive Therapeutics (NASDAQ:UNCY) and MIRA Pharmaceuticals (NASDAQ:MIRA) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, media sentiment, earnings, institutional ownership, risk, analyst recommendations and valuation.

Unicycive Therapeutics has a beta of 1.79, meaning that its stock price is 79% more volatile than the broader market. Comparatively, MIRA Pharmaceuticals has a beta of 1.52, meaning that its stock price is 52% more volatile than the broader market.

MIRA Pharmaceuticals has lower revenue, but higher earnings than Unicycive Therapeutics. Unicycive Therapeutics is trading at a lower price-to-earnings ratio than MIRA Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Unicycive Therapeutics	$680K	197.00	-$26.56M	-$1.75	N/A
MIRA Pharmaceuticals	N/A	N/A	-$10.44M	-$1.24	N/A

In the previous week, Unicycive Therapeutics had 8 more articles in the media than MIRA Pharmaceuticals. MarketBeat recorded 13 mentions for Unicycive Therapeutics and 5 mentions for MIRA Pharmaceuticals. MIRA Pharmaceuticals' average media sentiment score of 0.17 beat Unicycive Therapeutics' score of 0.04 indicating that MIRA Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Unicycive Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	12 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
MIRA Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Unicycive Therapeutics' return on equity of -91.50% beat MIRA Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Unicycive Therapeutics	N/A	-91.50%	-61.47%
MIRA Pharmaceuticals	N/A	-106.95%	-104.18%

40.4% of Unicycive Therapeutics shares are held by institutional investors. Comparatively, 35.2% of MIRA Pharmaceuticals shares are held by institutional investors. 6.0% of Unicycive Therapeutics shares are held by insiders. Comparatively, 19.9% of MIRA Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Unicycive Therapeutics currently has a consensus target price of $18.75, suggesting a potential upside of 289.81%. MIRA Pharmaceuticals has a consensus target price of $3.50, suggesting a potential upside of 308.07%. Given MIRA Pharmaceuticals' higher possible upside, analysts clearly believe MIRA Pharmaceuticals is more favorable than Unicycive Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Unicycive Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
MIRA Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Summary

Unicycive Therapeutics beats MIRA Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

Get MIRA Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MIRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MIRA vs. The Competition

Export

Metric	MIRA Pharmaceuticals	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$38.07M	$12.60B	$7.31B	$13.29B
Dividend Yield	N/A	2.63%	2.52%	12.57%
P/E Ratio	-0.69	792.28	274.02	25.69
Price / Sales	N/A	860.20	633.28	76.04
Price / Cash	N/A	88.64	77.80	52.76
Price / Book	3.43	10.62	10.44	6.32
Net Income	-$10.44M	$2.81B	$3.49B	$359.73M
7 Day Performance	12.96%	-0.08%	-0.66%	0.17%
1 Month Performance	8.83%	-1.31%	-3.16%	-3.27%
1 Year Performance	-36.47%	2.91%	15.15%	5.58%

MIRA Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MIRA MIRA Pharmaceuticals	2.4338 of 5 stars	$0.86 -5.3%	$3.50 +308.1%	-34.0%	$38.07M	N/A	N/A	2	Gap Up
IMUX Immunic	2.3475 of 5 stars	$10.85 +0.1%	$47.25 +335.7%	+5.6%	$147.93M	N/A	N/A	95
NMRA Neumora Therapeutics	2.4399 of 5 stars	$0.77 +11.9%	$6.57 +749.0%	-61.7%	$145.44M	N/A	N/A	63	News Coverage
MNOV MediciNova	2.3424 of 5 stars	$2.94 -11.1%	$7.75 +164.1%	+120.5%	$144.46M	$410K	N/A	6	High Trading Volume
NRXP NRx Pharmaceuticals	1.452 of 5 stars	$3.32 +0.8%	$34.50 +940.7%	+10.9%	$143.54M	$1.23M	N/A	29

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MIRA) was last updated on 9/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

MIRA Pharmaceuticals (MIRA) Competitors

MIRA vs. IMUX, NMRA, MNOV, NRXP, and UNCY

How does MIRA Pharmaceuticals compare to Immunic?

Summary

How does MIRA Pharmaceuticals compare to Neumora Therapeutics?

Summary

How does MIRA Pharmaceuticals compare to MediciNova?

Summary

How does MIRA Pharmaceuticals compare to NRx Pharmaceuticals?

Summary

How does MIRA Pharmaceuticals compare to Unicycive Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MIRA vs. The Competition

MIRA Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

MIRA Pharmaceuticals (MIRA) Competitors

MIRA vs. IMUX, NMRA, MNOV, NRXP, and UNCY

How does MIRA Pharmaceuticals compare to Immunic?

Which has higher earnings & valuation, IMUX or MIRA?

Which has more volatility and risk, IMUX or MIRA?

Is IMUX or MIRA more profitable?

Do analysts prefer IMUX or MIRA?

Does the media favor IMUX or MIRA?

Do institutionals & insiders hold more shares of IMUX or MIRA?

Summary

How does MIRA Pharmaceuticals compare to Neumora Therapeutics?

Do institutionals and insiders believe in NMRA or MIRA?

Which has better valuation and earnings, NMRA or MIRA?

Which has more risk and volatility, NMRA or MIRA?

Is NMRA or MIRA more profitable?

Do analysts recommend NMRA or MIRA?

Does the media favor NMRA or MIRA?

Summary

How does MIRA Pharmaceuticals compare to MediciNova?

Is MIRA or MNOV more profitable?

Do institutionals & insiders believe in MIRA or MNOV?

Which has more risk and volatility, MIRA or MNOV?

Which has better earnings and valuation, MIRA or MNOV?

Does the media prefer MIRA or MNOV?

Do analysts rate MIRA or MNOV?

Summary

How does MIRA Pharmaceuticals compare to NRx Pharmaceuticals?

Does the media prefer MIRA or NRXP?

Which has more volatility and risk, MIRA or NRXP?

Which has preferable earnings and valuation, MIRA or NRXP?

Do analysts prefer MIRA or NRXP?

Is MIRA or NRXP more profitable?

Do insiders and institutionals hold more shares of MIRA or NRXP?

Summary

How does MIRA Pharmaceuticals compare to Unicycive Therapeutics?

Which has more volatility and risk, UNCY or MIRA?

Which has higher valuation & earnings, UNCY or MIRA?

Does the media favor UNCY or MIRA?

Is UNCY or MIRA more profitable?

Do institutionals & insiders hold more shares of UNCY or MIRA?

Do analysts prefer UNCY or MIRA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MIRA vs. The Competition

MIRA Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools